Could a natural chemical be the key to safer heart failure treatment?

NCT ID NCT04113109

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study looks at why the heart failure drug LCZ696 (sacubitril/valsartan) can cause a sudden drop in blood pressure when people first start taking it. The researchers think a natural chemical called bradykinin, which the drug prevents from breaking down, might be responsible. To test this, adults with stable heart failure will receive LCZ696 along with either a drug that blocks bradykinin (icatibant) or a placebo, and their blood pressure and urine output will be compared. The goal is to understand the mechanism behind the blood pressure drop, which could help doctors use this life-saving medication more safely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
LCZ696 (sacubitril/valsartan, also known as Entresto) and icatibant (a bradykinin blocker)
What this could lead to
If bradykinin is found to drive the blood pressure drop seen with LCZ696, doctors could use this knowledge to start the drug more safely, reducing side effects and helping more people with heart failure benefit from it.
What could go wrong
This is a small, early mechanistic study, not a large outcome trial. The results may not change practice, and blocking bradykinin could have its own risks, such as affecting blood pressure regulation in unexpected ways.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.